Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

New York, NY – October 5, 2022 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on TALEN®-edited smart CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, M.A. and virtually on November 8-12, 2022.

Presentations include:

Poster presentation:

Cellectis will present a poster on TALEN®-edited smart CAR T-cells targeting MUC1- expressing solid tumors. MUC1 is a tumor-associated antigen that is overexpressed in triple-negative breast cancer (TNBC) and other solid tumor malignancies.

Title: Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth
Poster Number: 217
Presenter: Piril, Erler Ph.D., Scientist II, Immuno-Oncology, Cellectis
Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C

Poster presentation:

Cellectis will present a poster on innovative T-cell engineering strategies designed to increase the activity of CAR T-cells for solid tumors while mitigating toxicity risk.

Title: TALEN®-edited smart CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy
Poster Number: 325
Presenter: Shipra Das Ph.D., Senior Scientist & Team Leader Immuno-Oncology, Cellectis
Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C

Full text of the abstracts will be released on the SITC website at 8:00 a.m. EST on November 7, 2022.